JP2019517498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517498A5 JP2019517498A5 JP2018562918A JP2018562918A JP2019517498A5 JP 2019517498 A5 JP2019517498 A5 JP 2019517498A5 JP 2018562918 A JP2018562918 A JP 2018562918A JP 2018562918 A JP2018562918 A JP 2018562918A JP 2019517498 A5 JP2019517498 A5 JP 2019517498A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- weeks
- ctla
- administered
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 11
- 230000037396 body weight Effects 0.000 claims 10
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 8
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 190000005734 nedaplatin Chemical compound 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- -1 phenanthriplatin Chemical compound 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229950002860 triplatin tetranitrate Drugs 0.000 claims 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007372A JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
| JP2024141986A JP2024167282A (ja) | 2016-06-03 | 2024-08-23 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345463P | 2016-06-03 | 2016-06-03 | |
| US62/345,463 | 2016-06-03 | ||
| PCT/US2017/035808 WO2017210631A1 (en) | 2016-06-03 | 2017-06-02 | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007372A Division JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517498A JP2019517498A (ja) | 2019-06-24 |
| JP2019517498A5 true JP2019517498A5 (https=) | 2020-07-09 |
Family
ID=59054317
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562918A Pending JP2019517498A (ja) | 2016-06-03 | 2017-06-02 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 |
| JP2022007372A Pending JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
| JP2024141986A Pending JP2024167282A (ja) | 2016-06-03 | 2024-08-23 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007372A Pending JP2022058699A (ja) | 2016-06-03 | 2022-01-20 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
| JP2024141986A Pending JP2024167282A (ja) | 2016-06-03 | 2024-08-23 | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20190292260A1 (https=) |
| EP (2) | EP3463454A1 (https=) |
| JP (3) | JP2019517498A (https=) |
| KR (1) | KR20190015407A (https=) |
| CN (1) | CN109475634A (https=) |
| WO (1) | WO2017210631A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| SMT202500282T1 (it) * | 2015-11-18 | 2025-09-12 | Bristol Myers Squibb Co | Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4 |
| CN109475634A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体 |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2020081783A2 (en) * | 2018-10-18 | 2020-04-23 | Medimmune, Llc | Anti-ox40, anti-pd-l1 and anti-ctla-4 antibodies for treating tumors |
| WO2020086724A1 (en) | 2018-10-23 | 2020-04-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| MX2023007780A (es) * | 2021-01-08 | 2023-07-10 | Bristol Myers Squibb Co | Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. |
| TW202602492A (zh) * | 2024-04-05 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | 局限期小細胞肺癌之治療 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN109475634A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体 |
-
2017
- 2017-06-02 CN CN201780048326.3A patent/CN109475634A/zh active Pending
- 2017-06-02 WO PCT/US2017/035808 patent/WO2017210631A1/en not_active Ceased
- 2017-06-02 EP EP17729720.7A patent/EP3463454A1/en not_active Withdrawn
- 2017-06-02 US US16/306,383 patent/US20190292260A1/en not_active Abandoned
- 2017-06-02 JP JP2018562918A patent/JP2019517498A/ja active Pending
- 2017-06-02 EP EP24158972.0A patent/EP4386005A3/en active Pending
- 2017-06-02 KR KR1020187038117A patent/KR20190015407A/ko not_active Ceased
-
2021
- 2021-07-08 US US17/370,791 patent/US11767361B2/en active Active
-
2022
- 2022-01-20 JP JP2022007372A patent/JP2022058699A/ja active Pending
-
2023
- 2023-08-15 US US18/450,219 patent/US20240052035A1/en active Pending
-
2024
- 2024-08-23 JP JP2024141986A patent/JP2024167282A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517498A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| Tan et al. | Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer | |
| JP2019516711A5 (https=) | ||
| JP2019517511A5 (https=) | ||
| JP2022533578A5 (https=) | ||
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2016520082A5 (https=) | ||
| JP2019517505A5 (https=) | ||
| JP2023526259A5 (https=) | ||
| Karayama et al. | Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study | |
| US20090196871A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| Kubota et al. | Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer | |
| AU2015242786B2 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP7168575B2 (ja) | トリフルリジン／チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物 | |
| AU2002342678A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| Seliger et al. | Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum-and paclitaxel-pretreated epithelial ovarian cancer | |
| Barroso-Sousa et al. | The Clinical Development of Immune Checkpoint Inhibitors in Combination with Targeted Therapy in Breast Cancer | |
| EP1712234A1 (en) | Use of 4-Pyridylmethylphthalazines for Cancer Treatment | |
| HK40015395A (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| NZ552119A (en) | Use of a 4-pyridylmethylphthalazines for renal cancer treatment | |
| ZA200401184B (en) | Use of 4-pyridylmethylphthalazines for cancer treatment. |